<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01055899</url>
  </required_header>
  <id_info>
    <org_study_id>6R88-RA-0801</org_study_id>
    <nct_id>NCT01055899</nct_id>
  </id_info>
  <brief_title>Safety Study of a Single Dose of REGN88(SAR153191)in Patients With Rheumatoid Arthritis</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety and Tolerability of Subcutaneously Administered REGN88 in Subjects With Rheumatoid Arthritis Receiving Concomitant Methotrexate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the safety and tolerability (how the body reacts to the drug) of REGN88
      and placebo (an inactive substance that contains no medicine) in patients with Rheumatoid
      Arthritis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, randomized, double blind, placebo-controlled, single dose escalation
      study of the safety and tolerability of subcutaneously administered REGN88 in rheumatoid
      arthritis patients who are receiving concomitant methotrexate.

      Three (3) sequential dose cohorts of 5 subjects (4:1 active: placebo) will be dosed SC with
      REGN88 or placebo. Subjects who complete the study will participate in 14 study visits over
      16 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the safety and tolerability of a single dose of subcutaneously administered REGN88 in subjects with rheumatoid arthritis who are receiving concomitant treatment with methotrexate</measure>
    <time_frame>113 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the PK profile of a single subcutaneous (SC) dose of REGN88, and the immunogenicity of a single SC dose of REGN88</measure>
    <time_frame>113 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First dose of SC REGN88</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Second dose of SC REGN88</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Third dose of SC REGN88</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>REGN88</intervention_name>
    <description>Single SC Dose</description>
    <arm_group_label>Dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>REGN88</intervention_name>
    <description>Single SC Dose</description>
    <arm_group_label>Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>REGN88</intervention_name>
    <description>Single SC Dose</description>
    <arm_group_label>Dose 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female â‰¥ 18 years of age

          2. Subjects must weigh &gt; 50 kg and &lt; 100 kg

          3. Diagnosis of Rheumatoid Arthritis (RA) as defined by the 1987 revised American College
             of Rheumatology (ACR) criteria with disease duration of no less than 6 months and ACR
             class I-III

          4. For women of childbearing potential, a negative serum pregnancy test at the Screening
             Visit (Visit 1) and a negative urine pregnancy test at Day -1

          5. For men and women of childbearing potential, willingness to utilize adequate
             contraception and not become pregnant (or have their partner[s] become pregnant)
             during the full course of the study.

        Exclusion Criteria:

          1. A history of Listeriosis or active tuberculosis (TB)

          2. Persistent chronic or active recurring infection requiring treatment with antibiotics,
             antivirals, or antifungals within 4 weeks prior to the Screening Visit

          3. History of prior articular or prosthetic joint infection

          4. History of a hypersensitivity reaction, other than localized injection site reaction
             (ISR), to any biological molecule

          5. Significant concomitant illness such as, but not limited to cardiac, renal,
             neurological, endocrinological, metabolic or lymphatic disease that would adversely
             affect the subject's participation in this study

          6. Received administration of any live (attenuated) vaccine within 3 months prior to the
             Screening Visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allen Radin, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2010</study_first_submitted>
  <study_first_submitted_qc>January 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2010</study_first_posted>
  <last_update_submitted>September 27, 2013</last_update_submitted>
  <last_update_submitted_qc>September 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

